Table 3.

BK and JC human PyV serostatusa prior to cutaneous SCC diagnosis, and post SCC diagnosis, among 85 cases from the Skin Cancer Prevention Study

PyV serostatus postdiagnosis (n = 85)
PyV serostatus prediagnosisSeronegative, n (%)Seropositive, n (%)
BK
 Never seropositive1 (1.2)0 (0)
 Ever seropositive0 (0)84 (98.8)
JC
 Never seropositive10 (11.8)1 (1.2)
 Ever seropositive0 (0)74 (87.1)
  • aPyV infection was determined using seropositivity for the VP1 protein.